The purpose of this consortium is to build Team Science: bring together scientists, academia, clinicians, and researchers to interact, share and collaborate on research on bacteriophages and their lytic enzymes, with an aim to contribute towards phage/lysin therapy. In the wake of antimicrobial resistance (AMR), bacteriophages and their Lysin enzymes offer a promising and viable alternate/complement therapy to antibiotics. By leveraging the expertise and resources of the consortium, we hope to make phage therapy a safe and acceptable solution to growing threat of AMR.